CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma

Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Hironori Koga, Takuji Torimura,

Clin Mol Hepatol. 2022;28(3):575-579. Published online 2022 April 21 DOI: https://doi.org/10.3350/cmh.2022.0047

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma

Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Hironori Koga, Takuji Torimura,

Clinical and Molecular Hepatology. 2022;28(3):575-579

Link1

Link2 Link3

Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy

Masatoshi Kudo

Cancers. 2021;13(21):5475

Link1

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China

Hongyu Gong, Siew Chin ONG, Fan Li, Keying Zhao, Zhiying Weng, Zhengyou Jiang

. 2023;

Link1 Link2

Perfusion Change of Hepatocellular Carcinoma during Atezolizumab plus Bevacizumab Treatment: A Pilot Study

Ezinwanne Onuoha, Andrew D. Smith, Robert Cannon, Mohd Khushman, Harrison Kim

. 2022;

Link1 Link2

Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma – Authors' replys

Kyung-Hun Lee, Michael S Lee

The Lancet Oncology. 2020;21(9):e413

Link1 Link2

Updated Efficacy and Safety Data from IMbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma

Akash Roy

Journal of Clinical and Experimental Hepatology. 2022;12(6):1575-1576

Link1 Link2

Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy

Masatoshi Kudo

Liver Cancer. 2021;10(2):85-93

Link1 Link2

A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy

Masatoshi Kudo

Liver Cancer. 2020;9(2):119-137

Link1 Link2

Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi

Liver Cancer. 2021;11(2):180-181

Link1 Link2

Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Xu Yang†, Dongxu Wang†, Jianzhen Lin, Xiaobo Yang, Haitao Zhao

The Lancet Oncology. 2020;21(9):e412

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Clin Mol Hepatol has participated in CrossRef Text and Data Mining service since March 1, 2015.